Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.1 It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.